SAPCD2 and prostate cancer: Suppressor APC domain containing neuroblastoma (SAPCD2) (Zhang et al., 2022), has been reported to regulate Yap/Taz, MAPK, and mTOR signaling in various cancers, including colorectal (Luo et al., 2020) and prostate cancer (Sun et al., 2021).